Medicare Enrolled

Dr. Gnanesh Patel, MD

Rheumatology · Wilkes Barre, PA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
150 MUNDY ST, Wilkes Barre, PA 18702
5708247117
In practice since 2011 (15 years)
NPI: 1316238298 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Patel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Patel

Dr. Gnanesh Patel is a rheumatology specialist in Wilkes Barre, PA, with 15 years of NPI registration. Based on federal Medicare data, Dr. Patel performed 266,480 Medicare services across 1,851 unique beneficiaries.

Between the years covered by Open Payments, Dr. Patel received a total of $59,308 from 42 pharmaceutical and/or device companies across 1143 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Patel is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 15 years in practice ▲ Top 1% volume in PA $59,308 industry payments

Medicare Practice Summary

Medicare Utilization ↗
266,480
Medicare services
Top 1% in PA for rheumatology
1,851
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~17,765 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
77,400 $10 $53
Tocilizumab injection (Actemra) 66,120 $5 $7
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
59,200 $4 $12
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
31,475 $34 $74
Denosumab injection (Prolia/Xgeva) 25,200 $18 $25
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
3,450 $26 $159
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
1,308 $60 $138
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
1,008 $97 $556
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
456 $11 $53
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
292 $54 $265
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
170 $86 $191
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
137 $111 $229
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
93 $21 $159
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
80 $7 $318
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
26 $45 $170
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
24 $58 $127
Injection, methylprednisolone acetate, 40 mg 24 $6 $40
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
17 $48 $186
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
42.5% high complexity
56.8% medium
0.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$59,308
Total received (2018-2024)
Avg $8,473/year across 7 years
Top 11% in PA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
1,143
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32,618 (55.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,978 (28.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,712 (16.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,663
2023
$2,390
2022
$2,198
2021
$3,284
2020
$4,418
2019
$31,117
2018
$13,238

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$577
ABBVIE INC.
$375
UCB, Inc.
$310
Amgen Inc.
$294
Novartis Pharmaceuticals Corporation
$195
Radius Health, Inc.
$167
ANI Pharmaceuticals, Inc.
$141
Boehringer Ingelheim Pharmaceuticals, Inc.
$106
AstraZeneca Pharmaceuticals LP
$103
Organon Llc
$81
GlaxoSmithKline, LLC.
$63
Mallinckrodt Hospital Products Inc.
$61
E.R. Squibb & Sons, L.L.C.
$52
Fresenius Kabi USA, LLC
$45
PFIZER INC.
$41
Genentech USA, Inc.
$39
Alexion Pharmaceuticals, Inc.
$13
Top 3 companies account for 47.4% of 2024 payments
All-time payments by company (2018-2024) ›
AbbVie, Inc.
$26,744
UCB, Inc.
$11,436
AbbVie Inc.
$5,836
Amgen Inc.
$2,970
Janssen Biotech, Inc.
$2,534
Novartis Pharmaceuticals Corporation
$1,420
ABBVIE INC.
$1,146
PFIZER INC.
$1,138
Radius Health, Inc.
$746
Genentech USA, Inc.
$654
Janssen Scientific Affairs, LLC
$604
Lilly USA, LLC
$539
E.R. Squibb & Sons, L.L.C.
$375
Mallinckrodt Hospital Products Inc.
$362
GlaxoSmithKline, LLC.
$309
Flexion Therapeutics, Inc.
$304
AstraZeneca Pharmaceuticals LP
$258
Celgene Corporation
$253
Boehringer Ingelheim Pharmaceuticals, Inc.
$203
Mallinckrodt Enterprises LLC
$160
Alexion Pharmaceuticals, Inc.
$148
Mallinckrodt LLC
$145
ANI Pharmaceuticals, Inc.
$141
GENZYME CORPORATION
$128
Ferring Pharmaceuticals Inc.
$97
SANOFI-AVENTIS U.S. LLC
$86
Organon Llc
$81
Fresenius Kabi USA, LLC
$79
Novo Nordisk Inc
$57
Takeda Pharmaceuticals U.S.A., Inc.
$48
Actelion Pharmaceuticals US, Inc.
$47
Aurinia Pharma U.S., Inc.
$38
Organon LLC
$37
Cumberland Pharmaceuticals, Inc.
$33
HOSPIRA, INC.
$31
Merck Sharp & Dohme Corporation
$28
DePuy Synthes Sales Inc.
$25
Oxford Immunotec USA Inc
$16
MEDAC PHARMA, INC.
$15
Horizon Therapeutics plc
$15
Ultragenyx Pharmaceutical Inc.
$14
Bioventus LLC
$13
Top 3 companies account for 74.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · Aimovig · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Durolane · EUFLEXXA · EVENITY · EVUSHELD · Enbrel · FORTEO · HUMIRA · Humira · IDACIO · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · MONOVISC · OFEV · OPSUMIT · ORENCIA · ORTHOVISC · Otezla · Ozempic · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolia · REDITREX · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SOLIRIS · STELARA · STRENSIQ · SYNVISC-ONE · Strensiq · TALTZ · TAVNEOS · TREMFYA · TSPOT TB TEST · Tavneos · Tymlos · ULTOMIRIS · Uloric · XELJANZ · XOLAIR · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (55%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware.

Looking for a rheumatology specialist in Wilkes Barre?
Compare rheumatologists in the Wilkes Barre area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
13
Per 100K population
4.0
County median income
$62,321
Nearest hospital
GEISINGER BEHAVIORAL HEALTH CENTER NORTHEAST
9.7 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Patel is a mixed practice specialist, with above-average Medicare volume (top 1% in PA), with speaking/promotional industry engagement in the top 11% of PA peers, with 15 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Patel experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Patel performed 77,400 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Patel receive payments from pharmaceutical companies?
Yes. Dr. Patel received a total of $59,308 from 42 companies across 1,143 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patel's costs compare to other rheumatologists in Wilkes Barre?
Dr. Patel's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →